Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
2 of 8 appear on more than one
4 people on two or more of them
Lynn Stockwell is a pharmaceutical entrepreneur and serial SPAC sponsor based in Fort Lauderdale, Florida, who has served as Chief Executive Officer and Executive Chair of the Board of multiple blank-check companies focused on domestic drug manufacturing. She is the sole or managing member of the sponsors of Drugs Made In America Acquisition Corp. (Nasdaq: DMAA), which raised $200 million in its January 2025 IPO of 20 million units at $10.00 each, and Drugs Made In America Acquisition II Corp. (Nasdaq: DMII), which priced the largest SPAC IPO of 2025 in September 2025, raising $500 million through 50 million units at $10.00 each with Cantor as sole bookrunner. Stockwell described the strategy as targeting a $10 billion addressable market by onshoring pharmaceutical production to U.S. soil, reducing reliance on foreign sources, and leveraging a sovereign manufacturing platform. She has indicated plans for as many as four drug-related SPACs in total.
Stockwell's career in plant-based pharmaceuticals spans nearly four decades. She is the founder of Bright Green Corporation (Nasdaq: BGXX), a plant-based pharmaceutical research company that completed a direct listing in 2022; she has been a board member since its inception in 2019 and Chair of the Board since February 2024, and remains a director and 10 percent owner holding approximately 68.2 million shares. From 2015 to 2020, she was Managing Member of Bright Green Innovations, LLC, where she managed business, industry, and medical research relationships in compliance with federal legal standards. She also served as CEO and Chairwoman of PharmAGRI Capital Partners following a court-enforced merger with Bright Green Corporation, and has been identified as CEO and Chairwoman of PharmAGRI. Earlier in her career, she served as a director at a hospital, where she led fundraising initiatives advocating natural additives as alternatives to opioids, and she has sponsored biomedical research and clinical trials in plant-based bio-identical hormone replacement therapy. Her LinkedIn profile also lists her as Executive Director at Bethany Rehabilitation in the Denver area.
Stockwell's SPAC track record has been mixed. While DMAA and DMII successfully raised substantial capital, DMII disclosed significant governance and financial challenges in its 2025 annual report. The sponsor withdrew approximately $1.35 million from DMII's working capital account, leaving $812,113 due back that management deemed unlikely to recover and fully reserved as a current expected credit loss. In February 2026, the DMII board accepted Stockwell's resignation as CEO and Executive Chair, appointing Roger Bendelac as her successor, as the company faced a working capital deficit of $274,827, only $223 in cash, and substantial doubt about its ability to continue as a going concern within its 24-month transaction window. Management also identified material weaknesses in internal controls, including inadequate segregation of duties and insufficient review of related-party transactions.
Stockwell is actively engaged in healthcare advocacy and professional organizations. She is a member of the Association for Healthcare Philanthropy (AHP), the BioIndustry Association (BIA), where she focuses on scholarship opportunities for women in the life sciences, and the National Breast Cancer Coalition. Her strategic focus areas include advancing the role of plant-based drugs, which she notes constitute approximately 45 percent of controlled substances, promoting Schedule I and Schedule II plant-based therapeutics, investing in advanced domestic manufacturing technologies, and navigating complex regulatory landscapes to ensure compliance and innovation. No information about her formal educational background was available in the sources reviewed.
This record is keyed to SEC CIK 0001927032 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row.